Literature DB >> 26644844

Inmunohistochemical detection of mastocytes in tissue from patients with actinic prurigo.

Eduwiges Martínez-Luna1, Ronell Bologna-Molina2, Adalberto Mosqueda-Taylor3, Juan-Carlos Cuevas-González2, Erika Rodríguez-Lobato1, María-Abril Martínez-Velasco1, María-Elisa Vega-Memíje1.   

Abstract

BACKGROUND: Actinic prurigo (AP) is a type of photodermatosis, the pathophysiology of which has not been determined. AP has been suggested to be a hypersensitivity reaction to the presence of eosinophils and the local production of IgE.
MATERIAL AND METHODS: Descriptive study, using paraffin blocks of tissue that have been diagnosed with AP from the Dermopathology department, Hospital General Dr. Manuel Gea González. In 66 blocks from 63 patients, eosinophils were identified by hematoxylin and eosin staining, and mastocytes were labeled by immunohistochemistry. Three random microphotographs (40x) were used, and cell counts were calculated as the mean count in the 3 microphotographs.
RESULTS: Forty cases (63.5%) were female, and 23 (36.5%) were male. The mean age was 26.49 ±14.09 years; regarding the evolution time of the disease, the average was 11.93 years ±11.39. In 38 of 63 cases (60%), the lip, skin, and conjunctiva were affected clinically. In 22 of 63 cases (34%), AP cheilitis was the sole manifestation, and in 4 of 63 cases (6%), there were lesions in the skin and conjunctiva. The mean eosinophil count was 9 per case, the average number of mastocytes/field was 28.48 (range 0 to 66) Kruskal-Wallis p=0.001.
CONCLUSIONS: There are elements in AP that mediate the reaction of hypersensitivity type IV b, necessitating the identification of triggering factors. KEY WORDS: Actinic prurigo, eosinophil, hypersensitivity IV b, IgE, mastocytes.

Entities:  

Year:  2015        PMID: 26644844      PMCID: PMC4663070          DOI: 10.4317/jced.52823

Source DB:  PubMed          Journal:  J Clin Exp Dent        ISSN: 1989-5488


Introduction

Actinic prurigo (AP) is a chronic, inflammatory photodermatosis that affects the skin, lip, and conjunctival mucosa. AP primarily affects mixed-race and Amerindian populations who generally express the HLA-DR4 subtype DRB1*0407 allele (1-6) and live at altitudes over 1000 m above sea level (7). AP usually develops in infancy and predominates in females up 4:1, (8-11) affecting photoexposed areas. Clinically, erythematous papules, excoriation, and hematic scabs that form plaques are observed; pruritus develops, causing areas of lichenification (9-11). Cheilitis is present in nearly 85% of AP cases, and in 27% of cases, it is the sole manifestation of the illness (12). Between 45% and 62% of AP patients present with conjunctivitis and pseudopterygium formation (7,8,10). It evolves chronically, with partial remission (13). By histopathology, epithelial acanthosis, spongiosis and exulceration, and an abundance of eosinophils are seen in the dermis, and there is an infiltrate of nodular lymphoplasmocytes that can form lymphoid follicles, patognomonic image of AP´s chelitis (14,15). Dendritic follicular cells and plasma IgE-producing cells are also present, and IL-2 is produced by B and T lymphocytes (16). Elevated serum IgE has been reported in 10% to 50% of patients with AP and peripheral eosinophilia (17). Ultraviolet radiation in AP, (18-22) effecting local lymphocyte proliferation through the secretion of soluble compounds by keratinocytes, with no change in serum leucocyte levels (23-25). Mastocytes participate in inflammatory and allergic reactions. They are activated primarily through the high-affinity IgE receptor (FcεRI), which can bind the IgE-antigen complex to initiate a complex transduction of signals that culminate in the secretion of proinflammatory mediators and cytokines. Other mechanisms include anaphylatoxins that generated by activation of the complement pathway, bacteria through Toll-like receptors, the release of TNF-α by mastocytes that amplify a stimulus, and T lymphocyte stimulation (26-29). The presence of IgE-expressing eosinophils and mastocytes implicates a hypersensitivity reaction in the pathophysiology of AP (30). Generally, hypersensitivity reactions occur on exposure to an antigen through the activation of effector cells. There are 4 types of hypersensitivity reactions according the Gell and Coombs classification (31,32). Hypersensitivity reaction type IV, or retarded reaction, is mediated specifically by T lymphocytes, which produce cytokines that activate various antibodies. The IVa subtype corresponds to a Th1 response, which stimulates macrophages by secreting IFNy in which complement-fixing antibodies and complement isotypes are co stimulants of proinflammatory and CD8 cells. Conversely, the subtype IVb initiates a Th2 immune response in which lymphocytes T secrete IL-4, IL-5, and IL-13, which, through B cells that produce IgE and IgG4, stimulate eosinophils and mastocytes and inactivate macrophages. The high production of IL-5 causes eosinophilic inflammation, a characteristic of type IV hypersensitivity reactions (33-37). The aim of this study was to examine the presence of mast cells and eosinophils in AP to increase our understanding of its pat-hophysiology.

Material and Methods

This descriptive study we performed in the Dermopathology Department of Hospital General Dr. Manuel Gea González. The study samples were obtained from a pool of 40 tissue samples in skin with prurigo through a search of paraffin blocks using the clinical and histological criteria of AP. From this database, we drew the demographics and characteristics of the patients whose tissues were included (sex, age, clinical localization, family records, and evolution time of the disease). Using H&E slides for all cases, the diagnosis of AP was confirmed, and the presence of eosinophils and mastocytes was examined. The tissue block were, then slice and processed by immunohistochemistry. The tissues were deparaffinized, rehydrated, and subjected to antigenic recovery with 0.1% sodium citrate, pH 6.2, endogen peroxidase was inactivated (0.9% hydrogen peroxide), and the slides were incubated with 1% bovine serum albumin to block nonspecific sites. Washes were performed with PBS. Tissues were incubated for 45 minutes with polyclonal anti-CD 117 (Dako1:50), after which anti-mouse/anti-rabbit secondary antibody was applied. Streptavidin-peroxidase complex was added to the slides for 30 minutes, and the reactions were visualized with diaminobenzidine (Dako) and counterstained with Hills´ hematoxylin. The positive controls comprised 8 paraffin blocks of biopsies from various patients-2 healthy mucosal samples and 1 of each of the following: mucocele, venous lake, fibrous hyperplasia, traumatic cheilitis, sclerotic lichen, and granulomatous cheilitis. Eosinophil counts and immunohistochemistry evaluation were performed semi-quantitative, based on positivity to anti-CD 117 (Dako1:50) in the membrane and cytoplasm of mastocytes. Three 40x microphotographs were selected randomly for H&E stai-ning for eosinophils and immunohistochemistry for mastocytes, all of them with and cells of 5x4, which include a surface of 0.3mm2. Counting of the cells present in each of the cells was performed and it was added respectively so the number of the total positive cells was able to be known in the whole image. Average counts were calculated over the 3 microphotographs.

Results

Sixty-six blocks of tissue with a diagnosis of AP or AP cheilitis were selected. They had been diagnosed between 1995 and 2006 and contained enough biological material to be included in the study. Forty cases (63.5%) were female, and 23 (36.5%) were male. The mean age was 26.49±14.09 (range 7-63 years). The mean time in which the AP developed was 11.93 years ±11.39; time from diagnosis of AP ranged from 6 months to 45 years. Twenty-three patients (36.5%) had any immediate family member with a history of AP. In 38 of 63 (60%) cases, the lip, skin, and conjuntiva were clinically affected; in 22 cases (34%), AP cheilitis was the sole manifestation (only used for the study tissue of AP located in skin). Four cases (6%) had lesions in the skin and conjunctiva but not in the lip. In the 66 tissue samples that were diagnosed with AP and stained with H&E, the average number of eosinophils was 9 per case (Fig. 1). The average number of mastocytes in the mucosa of patients with AP was 28.48/field, ranging from 0 to 66 ( Table 1), versus 9.75/field in the control groups (range 5 to 16) and 7 mastocytes/field in healthy mucosa (Kruskal-Wallis p=0.001).
Figure 1

(HyE 40x) Presence of eosinophils in tissue with AP. Three micrographs were analyzed for each case, and the average of the 3 images was calculated.

Table 1

Number of positive mastocytes in AP samples.

(HyE 40x) Presence of eosinophils in tissue with AP. Three micrographs were analyzed for each case, and the average of the 3 images was calculated. Figure 2 shows representative immunohistochemistry staining of a randomly selected field. There were no significant differences in evolution time of disease or mean number of mastocytes per field. By calculation of Pearson´s correlation coefficient, we did not observe any linear relationship between mastocytes number and the evolution time of the disease ( Table 2) or between eosinophil number and the number of positive mastocytes.
Figure 2

Membrane and cytoplasmic reaction of anti-CD117 in tissue with AP in skin.

Table 2

Evolution time of AP and number of positive mastocytes.

Membrane and cytoplasmic reaction of anti-CD117 in tissue with AP in skin.

Discussion

Actinic prurigo occurs predominantly in women. Although the first signs of which develop in childhood, patients are usually diagnosed late. At the time that the clinical history is taken, it is common to record data on any relatives with the disease (7,12-15,38). The characteristics of our study sample—a predominance of female patients, early age of onset (mean 14.35 years), and 36.3% of patients with a family history of PA-are consistent with these rates. The number of mastocytes in normal skin increases from 44 to 75 mastocytes/mm2 and has an irregular distribution throughout the body, concentrating in the acral areas (39). In contrast, our AP patients had 189 mastocytes/mm2 at an enlargement of 40x and with a surface of 0.3 mm2. The density of mastocytes per field was greater in mucosa of patients with AP versus healthy mucosa and other lesions, including those with an inflammatory origin, implicating these cells in the pathophysiology of AP. In contrast, there were no significant differences in the quantity of mastocytes or time of evolution. Previous studies have reported the predominance of a Th2 response in AP, leading to the hypothesis that AP was a type I hypersensitivity reaction. In recent studies, however, when taking into account the presence of eosinophils, local production of IgE by plasma cells, increase in mastocytes number, detection of B and T cells, and participation of IL-2, an updated model suggests that the pathophysiology of AP is based on a type IV hypersensitivity reaction- specifically, subtype b-although subtype a can not be dismissed completely, based on these findings (16,24,36,39-41). Future studies should attempt to identify an antigen that, with exposure to ultraviolet light, triggers an inflammatory reaction and leads to the clinical manifestations of AP.

Conclusions

The higher density of mastocytes in samples from patients with actinic prurigo confirms the presence of all of the principal elements that mediate the reaction of late hypersensitivity type IV b, prompting us to hypothesize about the existence of a triggering allergen. More studies are required to resolve the pathophysiology of AP-specifically with regard to IL-2, IL-4, IL-5, and NK cells-and determine if and which apoptotic pathways are involved.
  25 in total

1.  Photosensitivity of the American Indian: terminology and historical aspects.

Authors:  J A Johnson; R M Fusaro
Journal:  J Am Acad Dermatol       Date:  1998-10       Impact factor: 11.527

2.  Actinic prurigo and HLA-DR4.

Authors:  R S Dawe; P Collins; J Ferguson; A O'Sullivan
Journal:  J Invest Dermatol       Date:  1997-02       Impact factor: 8.551

3.  Actinic or solar prurigo.

Authors:  M Magaña
Journal:  J Am Acad Dermatol       Date:  1997-03       Impact factor: 11.527

4.  Actinic prurigo: clinical features and prognosis.

Authors:  P R Lane; D J Hogan; M J Martel; B Reeder; J Irvine
Journal:  J Am Acad Dermatol       Date:  1992-05       Impact factor: 11.527

5.  Potential involvement of free radical reactions in ultraviolet light-mediated cutaneous damage.

Authors:  H S Black
Journal:  Photochem Photobiol       Date:  1987-08       Impact factor: 3.421

Review 6.  Actinic prurigo: an update.

Authors:  T Hojyo-Tomoka; E Vega-Memije; J Granados; O Flores; R Cortés-Franco; F Teixeira; L Domínguez-Soto
Journal:  Int J Dermatol       Date:  1995-06       Impact factor: 2.736

7.  Mast cell CD30 ligand is upregulated in cutaneous inflammation and mediates degranulation-independent chemokine secretion.

Authors:  Marie Fischer; Ilkka T Harvima; Ricardo F S Carvalho; Christine Möller; Anita Naukkarinen; Gunilla Enblad; Gunnar Nilsson
Journal:  J Clin Invest       Date:  2006-09-07       Impact factor: 14.808

8.  Effectors of inflammation in actinic prurigo.

Authors:  J E Arrese; L Dominguez-Soto; M T Hojyo-Tomoka; E Vega-Memije; R Cortés-Franco; E Guevara; G E Piérard
Journal:  J Am Acad Dermatol       Date:  2001-06       Impact factor: 11.527

9.  Lymphocyte subtypes and adhesion molecules in actinic prurigo: observations with cyclosporin A.

Authors:  Angela Umaña; Alberto Gómez; María Mélida Durán; Luisa Porras
Journal:  Int J Dermatol       Date:  2002-03       Impact factor: 2.736

10.  Follicular cheilitis. A distinctive histopathologic finding in actinic prurigo.

Authors:  R Herrera-Geopfert; M Magaña
Journal:  Am J Dermatopathol       Date:  1995-08       Impact factor: 1.533

View more
  4 in total

1.  The Immunogenetics of Photodermatoses.

Authors:  Chaw-Ning Lee; Tzu-Ying Chen; Tak-Wah Wong
Journal:  Adv Exp Med Biol       Date:  2022       Impact factor: 2.622

2.  Correlation of serum IgE levels and clinical manifestations in patients with actinic prurigo.

Authors:  Juan Carlos Cuevas-Gonzalez; Zahide Lievanos-Estrada; Maria Elisa Vega-Memije; Maria Teresa Hojyo-Tomoka; Luciano Dominguez-Soto
Journal:  An Bras Dermatol       Date:  2016 Jan-Feb       Impact factor: 1.896

3.  Risk factors associated with actinic prurigo: a case control study.

Authors:  Juan Carlos Cuevas-Gonzalez; María Elisa Vega-Memíje; Socorro Aída Borges-Yáñez; Erika Rodríguez-Lobato
Journal:  An Bras Dermatol       Date:  2017 Nov-Dec       Impact factor: 1.896

4.  Value of the toluidine blue test as an aid to determine the biopsy site in actinic prurigo cheilitis.

Authors:  Lily Margoth Cedeño-Suárez; María Elisa Vega-Memije; Juan Carlos Cuevas-González; Adalberto Mosqueda-Taylor
Journal:  Autops Case Rep       Date:  2021-03-12
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.